Intravenous thrombolytic use in patients enrolled in large ischemic core trials
| RESCUE-Japan LIMIT (EVT vs MM) | SELECT2 (EVT vs MM) | ASPECT-ANGEL (EVT vs MM) | |
| Thombolytic medication | Alteplase | Alteplase or tenecteplase | Alteplase or urokinase |
| Thrombolytic usage | 26.7% vs 28.4% | 20.8% vs 17.3% | 28.7% vs 28.0% |
| TESLA (EVT vs MM) | LASTE (EVT vs MM) | TENSION (EVT vs MM) | |
| Thombolytic medication | Alteplase | Unspecified | Alteplase |
| Thombolytic medication | 20.4% vs 20.3% | 34.6% vs 35.2% | 39% vs 34% |
EVT, endovascular therapy; MM, medical management.